Hydroxycarbamide treatment in sickle cell disease: Estimates of possible leukaemia risk and of hospitalization survival benefit

British Journal of Haematology

Volumn 167, Issue 5, 2014, Pages 687-691

  Castro, Oswaldo ^a   Nouraie, Mehdi ^a   Oneal, Patricia ^a  

^a HOWARD UNIVERSITY   (United States)

Author keywords

Acute myeloid leukaemia risk; Inpatient survival; Sickle cell disease; Treatment

Indexed keywords

HYDROXYUREA; ANTISICKLING AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD TRANSFUSION; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; HEALTH INSURANCE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEX RATIO; SICKLE CELL ANEMIA; AGE; ANEMIA, SICKLE CELL; DISEASE FREE SURVIVAL; FACTUAL DATABASE; LEUKEMIA, MYELOID, ACUTE; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGE FACTORS; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYUREA; LEUKEMIA, MYELOID, ACUTE; MALE; RISK FACTORS; SEX FACTORS; SURVIVAL RATE;

EID: 84925222180     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13093     Document Type: Article

References (23)

1. Al-Jam'a, A.H., Al-Dabbous, I.A., Al-Khatti, A.A. & Esan, F.G. (2002) Are we underestimating the leukemogenic risk of hydroxyurea. Saudi Medical Journal, 23, 1411-1413.
2. Baz, W., Najfeld, V., Yotsuya, M., Talwar, J., Terjanian, T. & Forte, F. (2012) Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia. Clinical Medicine Insights Oncology, 6, 149-152.
3. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., McMahon, R.P. & Bonds, D.R. (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. New England Journal of Medicine, 332, 1317-1322.
4. Darbari, D.S., Kple-Faget, P., Kwagyan, J., Rana, S., Gordeuk, V.R. & Castro, O. (2006) Circumstances of death in adult sickle cell disease patients. American Journal of Hematology, 81, 858-863.
5. Darbari, D.S., Wang, Z., Kwak, M., Hildesheim, M., Nichols, J., Allen, D., Seamon, C., Peters-Lawrence, M., Conrey, A., Hall, M.K., Kato, G.J. & Taylor Vi, J.G. (2013) Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study. PLoS ONE, 8, e79923.
6. Eichenauer, D.A., Thielen, I., Haverkamp, H., Franklin, J., Behringer, K., Halbsguth, T., Klimm, B., Diehl, V., Sasse, S., Rothe, A., Fuchs, M., Boll, B., von Tresckow, B., Borchmann, P. & Engert, A. (2014) Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood, 123, 1658-1664.
7. Ferster, A., Vermylen, C., Cornu, G., Buyse, M., Corazza, F., Devalck, C., Fondu, P., Toppet, M. & Sariban, E. (1996) Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood, 88, 1960-1964.
8. Ferster, A., Sariban, E. & Meuleman, N. (2003) Malignancies in sickle cell disease patients treated with hydroxyurea. British Journal of Haematology, 123, 368-369.
9. Haywood, C. Jr, Beach, M.C., Bediako, S., Carroll, C.P., Lattimer, L., Jarrett, D. & Lanzkron, S. (2011) Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. American Journal of Hematology, 86, 85-87.
10. Lanzkron, S., Haywood, C. Jr, Segal, J.B. & Dover, G.J. (2006) Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. American Journal of Hematology, 81, 927-932.
11. Lobo, C.L., Pinto, J.F., Nascimento, E.M., Moura, P.G., Cardoso, G.P. & Hankins, J.S. (2013) The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. British Journal of Haematology, 161, 852-860.
12. McGann, P.T. & Ware, R.E. (2011) Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Current Opinion in Hematology, 18, 158-165.
13. Morton, L.M., Dores, G.M., Tucker, M.A., Kim, C.J., Onel, K., Gilbert, E.S., Fraumeni, J.F. Jr & Curtis, R.E. (2013) Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood, 121, 2996-3004.
14. Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H. & Klug, P.P. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine, 330, 1639-1644.
15. Rauch, A., Borremeo, M., Ghafoor, A., Khoyratty, B. & Maheshwari, J. (1999) Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia [abstract]. Blood, 94, 415a.
16. Rees, D.C. (2011) The rationale for using hydroxycarbamide in the treatment of sickle cell disease. Haematologica, 96, 488-491.
17. Stallworth, J.R., Jerrell, J.M. & Tripathi, A. (2010) Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. American Journal of Hematology, 85, 795-797.
18. Steinberg, M.H., McCarthy, W.F., Castro, O., Ballas, S.K., Armstrong, F.D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L. & Waclawiw, M.A. (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematology, 85, 403-408.
19. Taylor, J.G., Darbari, D.S., Maric, I., McIver, Z. & Arthur, D.C. (2011) Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia. Annals of Internal Medicine, 155, 722-724.
20. Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D. & Terpos, E. (2010) The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood, 115, 2354-2363.
21. Wang, W.C., Ware, R.E., Miller, S.T., Iyer, R.V., Casella, J.F., Minniti, C.P., Rana, S., Thornburg, C.D., Rogers, Z.R., Kalpatthi, R.V., Barredo, J.C., Brown, R.C., Sarnaik, S.A., Howard, T.H., Wynn, L.W., Kutlar, A., Armstrong, F.D., Files, B.A., Goldsmith, J.C., Waclawiw, M.A., Huang, X. & Thompson, B.W. (2011) Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet, 377, 1663-1672.
22. Wilson, S. (2000) Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Annals of Internal Medicine, 133, 925-926.
23. Zumberg, M.S., Reddy, S., Boyette, R.L., Schwartz, R.J., Konrad, T.R. & Lottenberg, R. (2005) Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists. American Journal of Hematology, 79, 107-113.